We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has several recurrent and prognostic genetic alterations that have been characterized and are useful in the management of patients. Loss of 13q14.3 is the most common molecular alteration in CLL/SLL (~36% of all CLL/SLL cases) and as a sole abnormality often portends a favorable clinical course. Loss of 17p13.1(P53) or 11q22.3(ATM) are less common and are adverse prognostic markers in CLL/SLL. Trisomy 12, as detected by CEP12 FISH is a marker of intermediate prognosis. This panel includes IGH and t(11;14) FISH probes to aid in the differentiation of CLL/SLL cases from mantle cell lymphoma.
Organ: Blood/Bone Marrow
CPT Code(s): 88374x5, 88367. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Turnaround Time: Within 4-6 business days of receipt
Schedule: Monday - Friday
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR - • Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR - • Fresh tissue in RPMI